Jiangsu Recbio Technology and Shenzhen Rhegen Biotech established a joint JV to pool their knowledge of mRNA vaccine technology. Recbio has built a portfolio of 11 vaccine candidates, while Rhegen believes it has the world's leading mRNA technology. Rhegen  has developed three technology platforms for mRNA vaccines. The JV plans to apply the latest mRNA knowledge and novel adjuvant technology to develop a next-gen COVID-19 vaccine along with vaccines for other major infectious diseases and therapeutic cancer vaccines. More details.... Share this with colleagues: // //